A Chemical Compound with Possible Heterochromatin Remodeling Activity
Tech ID: 18729 / UC Case 2008-109-0
Background
Histone deacetylase inhibitors are currently being evaluated in clinical trials as anti-cancer drugs. They are likely to affect cancer cells because they alter the distribution of heterochromatin with resultant multiple downstream effects that cancer cells cope with only poorly. There is great interest in identifying additional chemical compounds that affect heterochromatin.
Technology Description
Histone deacetylase inhibitors are currently being evaluated in clinical trials as anti-cancer drugs. They are likely to affect cancer cells because they alter the distribution of heterochromatin with resultant multiple downstream effects that cancer cells cope with only poorly. There is great interest in identifying additional chemical compounds that affect heterochromatin.
Applications
Cancer drugs for p53-dependent tumors
Other Information
Categorized As
Related cases
2008-109-0
Contact
Maria Tkachuk / mtkachuk@uci.edu / tel: View Phone Number. Please reference Tech ID #18729.